Ms. Logan led the company for more than 12 years, and according to Tom D’Alonzo, chairman of Salix’s board of directors, Ms. Logan took “Salix from an early-stage commercial company with a market capitalization of approximately $200 million, one product and less than $25 million in annual revenues, to a leading gastroenterology-focused specialty pharmaceutical company with a multi-billion dollar market capitalization, more than 20 products and over $1 billion in annual revenues.”
Mr. D’Alonzo will be appointed acting CEO. Ms. Logan will remain a consultant to the company.
More articles on GI/endoscopy:
Global endoscopy market to reach $47B by 2020: 8 key trends
GI Dynamics names Michael Dale president & CEO
Diagnostic Endoscopy Center’s Dr. Stuart Waldstreicher honored
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
